Sept 1998

  international
  abstracts:
  home
  transplantation    

   alzheimer's issues:
   february 2003
   november 2002
   august 2002
   may 2002
   february 2002
   november 2001
   august 2001
   may 2001
   february 2001
   november 2000
   august 2000
   june 2000
   march 2000
   november 1999
   may 1999
   february 1999
   september 1998
   june 1998
   march 1998
   december 1997

IN THIS ISSUE

PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE

  • ApoE4 may increase AD susceptibility
  • Presenilins functions in AD
  • AB appears to have pivotal role in AD
  • Tau positive neurofibrillary are connected with AD cognitive symptoms
  • Causes, effects and treatment possibilities of AD

BIOLOGICAL MARKERS OF ALZHEIMER'S DISEASE

  • Recommended steps to establish AD biomarkers
  • Alterations of tau and its indications

DEMENTIA WITH LEWY BODIES VS ALZHEIMER'S DISEASE

  • DLB patients suffer from more hallucinations, confusion and Parkinson's than AD alone
  • MRI hippocampal volumetry is useful in distinguishing DLB from AD

 
EDITORIAL
FOREWORD		 PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE

The 6th International Conference on Alzheimer's Disease and Related Disorders took place in Amsterdam this July and the proceedings can be found in Neurobiology of Aging, vol 19, supplement 2. The plenary lectures were opportunities for critical reviews of the major etiological hypothesis, such as apolipoprotein E (Mahley et al), presenilins (Sisodia S), amyloid beta-peptide (Haass C), and the link to histopathology (Duykaerts et al). A symposium on AD has also been published in Neurology, vol 51, supplement 1, with a comprehensive review of the link between pathophysiology and treatment (Cummings et al).

Apolipoprotein E: Insights into the pathogenesis of Alzheimer's disease

(NEUROBIOLOGY AGING 1998;19(SUPPL 2):S74)
R.W. MAHLEY,
M. BUTTINI,
J. RABER,
R.E. PITAS,
L. MUCKE,
SAN FRANCISCO, CA

SORRY, THIS ABSTRACT IS NOT AVAILABLE

Function and dysfunction of presenilins in Alzheimer's disease

(NEUROBIOLOGY AGING 1998;19(SUPPL 2):S74)

S.S. SISODIA,
CHICAGO, IL

SORRY, THIS ABSTRACT IS NOT AVAILABLE

A central role of amyloid beta-peptide for Alzheimer's disease

(NEUROBIOLOGY AGING 1998;19(SUPPL 2):S221)

C. HAASS,
MANNHEIM, GERMANY

SORRY, THIS ABSTRACT IS NOT AVAILABLE

Histopathological course of Alzheimer disease

(NEUROBIOLOGY AGING 1998;19(SUPPL 2):S147)
C. DUYCKAERTS,
M.A. COLLE,
V. SAZDOVITCH,
D. SEILHEAN,
J.-J. HAUW,
PARIS, FRANCE

SORRY, THIS ABSTRACT IS NOT AVAILABLE

Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities

(NEUROLOGY 1998;51(SUPPL 1):S2-S17)
JEFFREY L. CUMMINGS, MD,
HARRY V. VINTERS, MD,
GREGORY M. COLE, PHD,
ZAVEN S. KHACHATURIAN, PHD,
LOS ANGELES, SEPULVEDA, CA,
POTOMAC, MD

To view abstract in
PubMed

BIOLOGICAL MARKERS OF ALZHEIMER'S DISEASE

EDITORIAL
COMMENT 		There is a great interest in the study of biological markers that could indicate who is at risk of AD, who is in the presymptomatic stage, and what experimental treatment can modify the course of disease. A working group of the Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging has published a Consensus Report on this important issue. As commented upon by J. Growdon in an accompanying editorial (Annals of Neurology 1998;44:6-7), the report by Kanai et al on the high levels of tau in cerebrospinal fluid of persons with AD comes very close to meeting the requirements of that Consensus Report.

Consensus report of the working group on:
molecular and biochemical markers of Alzheimer's disease

THE RONALD AND NANCY REAGAN RESEARCH INSTITUTE OF THE ALZHEIMER'S ASSOCIATION AND THE NATIONAL INSTITUTE ON AGING WORKING GROUP,
BETHESDA, MD

To view abstract in
PubMed

Longitudinal study of cerebrospinal fluid levels of tau, Abeta1-40, and Abeta1-42(43) in Alzheimer's disease: a study in Japan

(ANN NEUROL 1998;44:17-26)
M. KANAI, MD,
E. MATSUBARA, MD, PHD,
K. ISOE, MD, PHD,
K. URAKAMI, MD, PHD,
K. NAKASHIMA, MD, PHD,
ET AL,
TOKYO, JAPAN

To view abstract in
PubMed

 

DEMENTIA WITH LEWY BODIES (DLB)
VERSUS ALZHEIMER'S DISEASE

EDITORIAL
COMMENT 		DLB is considered by many as the second most common cause of degenerative dementia after AD, and may be very responsive to cholinesterase inhibitors such as tacrine or donepezil. Ballard et al presented in Amsterdam their data supporting the Criteria for Diagnosis proposed by the Consortium on DLB (Neurology 1996;47:1113-1124). These crtieria are also useful for volumetric MRI studies (Hashimoto et al).

Clinical symptoms in dementia with Lewy Bodies:
a prospective clinical and neuropathological
comparative study with Alzheimer's disease

(NEUROBIOLOGY AGING 1998;19(SUPPL 2)S204-S205)
C.G. BALLARD,
C. HOLMES,
I.G. MCKEITH,
K. LOWERY,
J.T. O'BRIEN,
R.H. PERRY,
NEWCASTLE UPON TYNE, UK

SORRY, THIS ABSTRACT IS NOT AVAILABLE

Medial temporal and whole-brain atrophy in dementia
with Lewy bodies: a volumetric MRI study

(NEUROLOGY 1998;51:357-362)
M. HASHIMOTO, MD,
H. KITAGAKI, MD,
T. IMAMURA, MD,
N. HIRONO, MD,
ET AL,
HIMEJI, JAPAN

To view abstract in
PubMed